Posts Tagged ‘Major Depressive Disorder’

Psychiatry bible ‘turns sorrow into sickness’

Saturday, December 3rd, 2011

The Age
By Jill Stark
December 4, 2011

IT’S been branded a “dangerous public experiment” that could turn normal human experiences into an epidemic of mental illness with healthy people being drugged unnecessarily.

In radical changes to the way mental health conditions are diagnosed, what was once considered a child’s temper tantrum could be labelled ”disruptive mood dysregulation disorder”. If a widow grieves for more than a fortnight she might be diagnosed with ”major depressive disorder”.

If a mother in a custody battle tries to turn a child against the father, it might create ”parental alienation disorder”.

These are among new conditions proposed for the fifth edition of the psychiatrist’s bible, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), due to be finalised next year.

Some doctors in Australia are arguing the revised manual – used globally to diagnose mental disorders – is pathologising unhappiness.

The changes have also caused an international outcry, with the American Counselling Association, American Psychological Association, the British Psychological Society and others calling for the draft of the new edition to be independently reviewed.

They fear it is so inclusive, it risks labelling millions of healthy people as mentally ill.

”It’s such a narrow and limited view of human experience, to want to reduce every bit of suffering to medical diagnosis,” said Jon Jureidini, professor of psychiatry at the University of Adelaide. He said the changes would lead to increased prescribing.

The authors say ”misinformation” about the manual, produced by the American Psychiatric Association since 1952, is creating unnecessary fear and any inclusions will be based on robust scientific evidence. Psychiatrist Ian Hickie, director of Sydney University’s Brain and Mind Research Institute, rejects claims that the new manual would medicalise unhappiness. ”When people are in pain and suffering elsewhere we don’t say people are pathologising that. We say, let’s try and do the best we can to relieve that and get them back to function in the appropriate way,” Professor Hickie said.

The rift reflects division within the mental health community over a global rise in the use of antidepressants, stimulants and antipsychotics, with many clinicians critical of drugs with potentially serious side effects being favoured over more costly talk-based therapies. Others argue that medication can be life-saving where other therapies have failed. The inclusion of conditions such as attention deficit hyperactivity disorder (ADHD) and autism in previous DSM editions is believed to have contributed to increased prescribing.

In the new edition, the diagnosis threshold for some existing disorders is also being lowered so that

over the death of a loved one can qualify as a major depressive illness.

The authors of DSM-5, however, argue that a bereaved person who is suffering from major depression is currently ineligible for that diagnosis, preventing them from getting help if they need it.

”A broad range of evidence … shows that there are little to no systematic differences between individuals who develop a major depression in response to bereavement and in response to other severe stressors – such as being … raped … or the loss of your treasured job,” Dr Kenneth Kendler, a member of the DSM-5 mood disorders group, said.

The changes also mean children only have to display six of 13 possible symptoms for a diagnosis of ADHD, compared with six of nine in the previous manual.

”Under the new criteria it’s almost harder not to get diagnosed with ADHD than it is to get diagnosed with it,” Martin Whitely, a West Australian Labor MP and anti-ADHD medication campaigner, said. ”There were about 60,000 Australian children on ADHD medications in 2010 – a lot of money has gone into marketing and selling the disease.”

One of the manual’s biggest critics is the man who developed the last edition, American psychiatrist Allen Frances. He told The Sunday Age the fact that the authors of the new edition have described it as a ”living document” makes it a ”dangerous public health experiment”.

”The DSM-5 is used in real life-and-death decisions – it shouldn’t be a set of hypotheses to be tested,” he said. ”The worst outcome of this would be all these suggestions get included and a lot of people get medicine they don’t need. But an almost equally bad outcome would be that psychiatry gets so tarred by this aberration that people who really need psychiatry and need the medicine stop taking it.”

http://www.theage.com.au/national/psychiatry-bible-turns-sorrow-into-sickness-20111203-1ocmm.html

« Return to news items


Share

Selling Depression—Adding New Spin and Urgency to Depression Drug Sales

Tuesday, June 21st, 2011

CounterPunch – June 19 Edition

by Martha Rosenberg

The discovery that many people with life problem or occasional bad moods would willingly dose themselves with antidepressants sailed the drug industry through the 2000s. A good chunk of the $4.5 billion a year direct-to-consumer advertising has been devoted to convincing people they don’t have problems with their job, the economy and their family, they have depression. Especially because depression can’t be diagnosed from a blood test.

Unfortunately, three things dried up the depression gravy train for the drug industry. Blockbusters went off patent and generics took off, antidepressants were linked with gory and unpredictable violence, especially in young users and — they didn’t even work, according to medical articles!

That’s when the drug industry began debuting the concept of “treatment resistant depression.” It wasn’t that their drugs didn’t work (or you didn’t have depression in the first place), you had “treatment resistant depression.” Your first expensive and dangerous drug needed to be coupled with more expensive and dangerous drugs because monotherapy, one drug alone, wasn’t doing the trick!

You’ve got to admire the drug industry’s audacity with this upsell strategy. Adding drugs to your treatment resistant depression triples its take, patients don’t know which drug is working so they’ll take all of them and the defective drugs are exonerated! (Because the problem is you.)

Now the drug industry has a new whisper campaign to keep the antidepressant boat afloat. Your depression is “progressive.”

Once upon a time, when depression was neither seasonal, atypical, bipolar or treatment resistant, it was considered to be a self-limiting disease. In fact, just about the only good thing you could say about depression was it wouldn’t last forever.

But now, the drug industry is giving depression the don’t-wait scare treatment like coronary events (statins), asthma attacks (“controller” drugs) and thinning bones (Sally Field). If you don’t hurry and take medication, your depression will get worse!

“Depressive episodes become more easily triggered over time,” floats an article on the physician Web site Medscape (flanked by ads for the antidepressant Pristiq.) “As the number of major depressive episodes increase, the risk for subsequent episodes is predicted more from the number of prior episodes and less from the occurrence of a recent life stress.” The article, unabashedly titled “Neurobiology of Depression: Major Depressive Disorder as a Progressive Illness,” is written by Vladimir Maletic who happens to have served on Eli Lilly’s Speaker’s Bureau, says the disclosure information, and whose co-authors are each employees and/or Lilly shareholders.

On WebMD, a sister site to Medscape, the depression sell is even less subtle. An article called Recognizing the Symptoms of Depression, smothered with five ads for the Eli Lilly antidepressant, Cymbalta, submits, “Most of us know about the emotional symptoms of depression. But you may not know that depression can be associated with many physical symptoms, too.”

Depression may masquerade as headaches, insomnia, fatigue, backache, dizziness, lightheadedness or appetite problems mongers the article. “You might feel queasy or nauseous. You might have diarrhea or become chronically constipated.” And here, you thought it was something you ate!

The danger with these symptoms says the article is that you would fail to diagnose yourself as suffering from a psychiatric problem and buy an over-the-counter drug like a normal person. “Because these symptoms occur with many conditions, many depressed people never get help, because they don’t know that their physical symptoms might be caused by depression. A lot of doctors miss the symptoms, too.”

But when head and backaches aren’t labeled as depression, the drug industry make no money and insurance rates could stop climbing from over-treatment with unnecessary, expensive and dangerous psychoactive drugs!

To prevent such goring of marketshare, the article (whose content was “selected and controlled by WebMD’s editorial staff and is funded by Lilly USA,” an original WebMD financial partner according to the Washington Post) counsels worry about physical symptoms. “Don’t assume they’ll go away on their own.” Symptoms may “need additional treatment” and “some antidepressants, such as Cymbalta and Effexor, may help with chronic pain, too.”

Before direct-to-consumer advertising, the health care system was devoted to preventing over-treatment and assuring patients they were probably okay. Who remembers “Take two aspirin and call me in the morning”? Now patients are assured they probably aren’t okay but probably have a progressive disease. Luckily their disease can be treated with progressive prescriptions from pharma.

http://www.counterpunch.org/rosenberg06172011.html

« Return to news items


Share

A mother’s grief — without time limits

Wednesday, September 8th, 2010

by Marianne Leone

The Boston Globe, September 8, 2010

FIVE YEARS ago, I found my 17-year-old son dead in his bed, and apparently five years is too long to be manifesting the symptoms of sadness: sleeplessness, the sudden and inexplicable onset of overwhelming memories and tears, the occasional entire day spent lying in bed. My time was up two weeks after we found him, according to the proposed fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. If the new edition is approved, my symptoms will be diagnosed as a major depressive disorder.

I don’t go to a psychiatrist. I don’t take anti-depressant drugs. I don’t judge anyone who does. But I bristle at the idea of a group of psychiatrists giving me an arbitrary cutoff date for how long I am allowed to grieve.

My mother died six months before my son, my favorite aunt four months after him, my favorite uncle and the family dog a year later, along with my fictional television son on “The Sopranos.’’ Does that appalling list net me a few extra weeks grace from the people who want me to be a regular customer of Big Pharma? (OK, maybe the fictional son is a stretch.)

I wrote a book about my son Jesse, a memoir celebrating his life and mourning his death that was published yesterday. Most people ask me whether it was “cathartic’’ to write the book, a tremor of hope fluttering under their hesitant words. Catharsis means “the purging of emotions.’’ But Jesse hasn’t been disappeared from my life, Soviet-style. His memory is with me always, and sometimes it makes me cry because I miss him so much, because it hurts to see his friends becoming fine men when he didn’t get the chance, because I want to hold him with a longing that is visceral, even after he’s five years gone.

My mother grew up in the Abruzzo region of Italy, where the inhabitants of that old culture have experienced war, earthquakes, famine. They are not afraid to acknowledge death and the sadness that follows; a folk song about death is called “scura mai’’ — you have left me dark. They’re not afraid to represent the archetypical mother, Mary, with seven swords in her heart after the death of her Son. What are we afraid of here in the United States?

Since Jesse died, I have felt joy. I have even laughed until tears came to my eyes. I have written a book and essays, I have acted on television and in film, I have hosted huge family parties.

But, full disclosure: I have taken to my bed for the entire day sometimes, on Jesse’s birthday, and on the January date I found him dead. Because what makes more sense to me, the actual person who has suffered a loss, are the words C.S. Lewis’s character speaks in the film “Shadowlands’’: “The pain now is part of the happiness then. That’s the deal.’’

And if the shrinks think that’s a major depressive disorder, they’re the crazy ones, not me.

Read the article here: http://www.boston.com/bostonglobe/editorial_opinion/oped/articles/2010/09/08/a_mothers_grief__without_time_limits/

For information on the book Knowing Jesse – http://search.barnesandnoble.com/Knowing-Jesse/Marianne-Leone/e/9781439183922/

« Return to news items


Share

Glaxo Still Haunted by Faked Paxil Studies in Kids; Crooked psychiatrist expected to plead guilty to criminal charges today

Thursday, August 19th, 2010

“The use of Paxil in children became extremely controversial after it emerged that GSK knew for 15 years, but didn’t tell anyone until 2006, that the drug may carry a risk for suicide. The drug now carries a black-box warning for suicide risk in children.”

BNET
By Jim Edwards
August 19, 2010

A crooked doctor who faked data in a GlaxoSmithKline (GSK) study of the antidepressant Paxil in children pled guilty to criminal charges today, causing groans among GSK’s senior management as the company hopes to fend off a different criminal investigation into whether it manipulated clinical data on its diabetes drug, Avandia. She was sentenced to 13 months in prison.

The two cases are technically completely separate, but they’re both about data manipulation. GSK has been accused of sitting on data showing risks on both drugs; and the FDA previously shut down one of GSK’s factories where both drugs were made.

Thus, the expected guilty plea of Dr. Maria Carmen Palazzo today is a reminder to managers everywhere that cutting ethical corners can cause unwanted chickens to return to their roosts, even years later.

Palazzo was indicted in 2007 on 40 counts of defrauding Medicare and Medicaid at her New Orleans clinic, and 15 counts of conducting fraudulent clinical trials. The charges followed an FDA accusation that she had enrolled 26 children in studies of Paxil for obsessive-compulsive disorder and major depressive disorder. She included children in the trial — which was given the cutesey nickname “Kiddie-Sads-Present and Lifetime” — who did not have the diagnoses being studied. GSK gave her more than $5,000 for each child she enrolled.

At trial, Palazzo was convicted on 39 counts of healthcare fraud and was sentenced to 87 months in prison and forfeiture of $655,000. The clinical trial fraud charges were thrown out, but prosecutors appealed and won a ruling this year reinstating those charges. That appears to be the reason Palazzo is reappearing in court to make a plea.

The use of Paxil in children became extremely controversial after it emerged that GSK knew for 15 years, but didn’t tell anyone until 2006, that the drug may carry a risk for suicide. The drug now carries a black-box warning for suicide risk in children.

Read entire article here:  http://www.bnet.com/blog/drug-business/10-years-later-glaxo-still-haunted-by-faked-studies-of-paxil-in-kids/5545

Read more about Palazzo here:
http://medicaresmostwanted.blogspot.com/2007/06/dr-maria-carmen-palazzo-has-been.html

« Return to news items


Share

IMS Health Canada: New study shows psychiatric drug side effects putting people at risk of an early death

Monday, June 14th, 2010

The Vancouver Sun
By Sharon Kirkey
June 14, 2010

The risk of coronary heart disease and a cluster of conditions known as metabolic syndrome increases soon after otherwise healthy, but depressed people are started on psychiatric drugs, putting them at risk for an early death, Canadian researchers are reporting.

Antidepressants, antipsychotics and other psychoactive drugs are the second most-prescribed drug class in the country, second only to cardiovasculars, according to prescription drug-tracking firm IMS Health Canada.

Across Canada, retail pharmacies last year dispensed 61.2 million prescriptions for psychotherapeutics, worth nearly $2.4 billion.

“Usually five of the top 10 prescribed medications worldwide are psychiatric drugs. We need to start looking at the impact of these medications on other systems,” says Dr. Valerie Taylor, an assistant professor in psychiatry and behavioral neurosciences at St. Joseph’s health care and McMaster University in Hamilton.

In a study published this week in the Canadian Journal of Psychiatry, Taylor and her colleagues followed 52 patients, age 16 to 40, newly diagnosed with bipolar disorder or major depressive disorder.

Many were university students who had become ill for the first time. All were “treatment naive” — they had never before been treated for a psychiatric illness.

At the start of the study, researchers measured waist circumference, blood pressure, blood fats and other markers of metabolic syndrome — the name for a grab-bag of health problems that increase the risk of diabetes and cardiovascular disease.

People with metabolic syndrome are twice as likely to die from, and three times as likely to have a heart attack or stroke compared to people without the disorder. They also have up to a nine-fold greater risk of developing type 2 diabetes.

Read entire article:  http://www.vancouversun.com/health/Psychiatric+drugs+carry+serious+physical+health+risks/3153278/story.html

« Return to news items


Share

“Psychiatry’s ‘bible’ could roll out a whole new list of disorders—and more prescriptions for psychoactive drugs”

Friday, April 30th, 2010

The Gazette
By Sharon Kirkey
April 26, 2010

As Dr. Allen Frances read through the list of proposed changes to psychiatry’s bible of mental sickness, alarms started ringing in his own mind.

“I was surprised,” the renowned U.S. psychiatrist says, “that the proposals managed to be much worse than my most pessimistic expectations.”

By the time he was finished reading, Frances had calculated that the recommendations contained within the first draft for the fifth and latest revision of the Diagnostic and Statistical Manual of Mental Disorders – a hugely influential book used daily by doctors worldwide, psychiatry’s official classification of all the ways humanity can go “mad” – could unnecessarily trigger wholesale “epidemics” of mental illness and expose millions more adults and children to potentially harmful psychiatric drugs.

Frances, more than most, knows the kind of surprises that may be lurking.

He chaired the task force that wrote the current edition of the manual – referred to as DSM-IV – which Frances says is a book that unintentionally contributed to vast and sudden increases in the diagnosis of attention-deficit hyperactivity disorder, autism and childhood bipolar disorder (manic depression), after it made changes in those definitions.

Rates of bipolar disorder alone jumped 40-fold in the U.S. after the definition was broadened to suggest that children don’t have to experience the typical manic symptoms seen in adults to be diagnosed bipolar – and that depression in kids can be a persistent irritable mood.

Read entire article:  http://www.montrealgazette.com/news/canada/Psychiatry+bible+could+roll+whole+list+disorders/2951855/story.html#ixzz0mbCzBKaU

« Return to news items


Share

Psychiatry’s latest mental disorders—”Creativity? There’s a pill for that. Not to mention nonconformity and quirkiness”

Tuesday, April 27th, 2010

Not to mention nonconformity and quirkiness — the definition of mental illness changes

Canada.com
By Sharon Kirkey
April 27, 2010

Since 1950, man has landed on the moon, made computers commonplace and harnessed nuclear power.

We’re obviously using our minds to the fullest. Yet the number of ways we can go officially crazy has nearly tripled.

The hugely influential reference book used by psychiatrists and other mental health professionals the world over to diagnose mental illness — the Diagnostic and Statistical Manual of Mental Disorders — currently lists 357 types of psychiatric afflictions, up from 128 when the first volume was published in 1952.

The psychiatric establishment says it has learned to detect more mental illness in the population than was possible a half-century ago, and that science has advanced to the point that the broadly defined disorders of the past are now seen with much greater resolution, yielding many more specific conditions.

We’re not expanding the domain, they argue, as much as we’re refining it.

But skeptics say it is less about advances in brain science and more about psychiatry shuffling more and more behaviours and reactions to life’s letdowns into boxes of mental dysfunction and assigning them codes, and that we risk becoming so overdiagnosed and overmedicated, we’ll be like the patient in The New Yorker cartoon, who asks his psychiatrist: “Could we up the dosage? I still have feelings.”

“The unavoidable conclusion is that we’ve narrowed healthy behaviour so dramatically that our quirks and eccentricities — the normal emotional range of adolescence and adulthood — have become problems we fear and expect drugs to fix,” says Christopher Lane, author of Shyness: How Normal Behavior Became a Sickness.

It’s not enough that people sometimes want to be alone, Lane says. Solitude? According to the DSM, including its criteria for “avoidant” and “schizoid”personality disorders, that could be viewed as a sign of mild psychosis, he warns. Feeling restless, keyed up or on edge could be markers of generalized anxiety disorder, and trouble sleeping a symptom of a major depressive disorder.

The more diagnostic categories added to the DSM, the more broadly they’re defined, the bigger the market of potential new drug customers grows, says Stuart Kirk, professor of social welfare at the University of California Los Angeles School of Public Affairs. Within each revision of psychiatry’s bible, pharmaceutical companies see a “bonanza” of marketing possibilities, he says.

Read entire article:  http://www.canada.com/life/Creativity+There+pill+that/2955948/story.html

« Return to news items


Share

LewRockwell.com – The Big Government-Big Pharma Complex: Disease Mongering for Fear and Profit

Sunday, October 11th, 2009

Karen De Coster
LewRockwell.com
October 10, 2009

Ronit Ridberg has given the world a marvelous look into the fraudulent, Big Government-Big Pharma complex with his documentary film, Big Bucks, Big Pharma: Marketing Disease and Pushing Drugs. It’s a bit dated, from 2006, but certainly, that is no hindrance to the message of the film. It’s an hour long, but worth every minute of your time. Below, I have compiled a list of some interesting points from the film. I have also included a lot of my own thoughts from my research on issues brought up in the film, so not all of the material I have presented is contained within the documentary.

Big Pharma is a monster that’s long been out of control, and that is due to its chief enabler, big government, whose bureaucrats profit immensely from promoting Big Pharma’s agenda to grow and protect its profits. In spite of what Michael Moore would say, this arrangement is not capitalism, or as he means it, the free market. It is state capitalism, or, as some may call it, socialist corporatism.

Industry professionals discuss how Big Pharma normalizes obscure health problems, making them appear common in order to create a new market with a demand for prescription drugs. One Doc interviewed calls this “disease mongering.” For example, after the commercials appeared from GlaxoKlineSmith, suddenly everyone seemed to have Restless Leg Syndrome.

Perhaps a most disturbing trend brought up in the film is the wacky, wild world of “things just ain’t right” disorders. Whether it’s “generalized anxiety disorder,” “major depressive disorder,” “panic disorder,” “acute social phobia,” or finally, the celebrated “social anxiety disorder,” there’s a disorder to fit you and explain away your day-to-day problems.

Read entire article: http://www.lewrockwell.com/decoster/decoster165.html

« Return to news items


Share

No Surprise: Psychiatrist pushing “Depression” testing for 3-yr-olds connected to three drug companies

Monday, August 17th, 2009

Martha Rosenberg
The Epoch Times
August 17, 2009

Try to access the Web site of the Archives of General Psychiatry, and you may have to abide an ad for the antidepressant Pristiq before you can enter. (JAMA and its Archives Journals “do not endorse the advertised product,” you’ll be assured.)

But look for a pharma affiliation for the author of the article “Preschool Depression,” Joan L. Luby, M.D., in the August issue, and you’ll be told no “financial disclosure” was reported. Not that “Dr. Luby has received grant/research support from Janssen, has given occasional talks sponsored by AstraZeneca, and has served as a consultant for Shire Pharmaceutical,” as a 2006 article in Journal of the American Academy of Child and Adolescent Psychiatry says.

Even though the pharmaceutical industry has 27 million Americans—10 percent of the population—on antidepressants, thanks to direct to consumer advertising, it is looking for depression in preschoolers. And guess what? It’s finding it!

Read entire article: http://www.theepochtimes.com/n2/content/view/21114/

« Return to news items


Share